扩张型心肌病临床免疫治疗进展

发布时间：2018-10-20 12:21

【摘要】：扩张型心肌病(DCM)目前仍无特异性治疗方法。DCM患者体内抗心肌自身抗体和炎性因子失调所介导的心肌免疫损伤在DCM的发展中有重要作用,针对相应免疫靶点治疗(如免疫吸附、药物阻断抗心肌抗体作用途径、中药免疫调节和细胞移植等)是近年研究者探索DCM临床免疫治疗的热点,它们将有助于实现在规范化心力衰竭的治疗基础上进一步改善DCM心脏功能和预后的目的。
[Abstract]:There is no specific treatment for dilated cardiomyopathy (DCM) at present. Myocardial immune damage mediated by anti-myocardial autoantibodies and inflammatory factor disorders in patients with DCM plays an important role in the development of DCM. In recent years, it has been a hot topic for researchers to explore the clinical immunotherapy of DCM, such as blocking the action of anti-myocardial antibody, the immunomodulation of traditional Chinese medicine and cell transplantation, etc. They will help to further improve cardiac function and prognosis of DCM on the basis of standardized heart failure therapy.
【作者单位】：华中科技大学同济医学院附属协和医院心内科;
【分类号】：R542.2

【参考文献】